So-Jung Shim1, Mei Chan1,2, Louisa Owens1,2, Adam Jaffe1,2, Bernadette Prentice1,2, Nusrat Homaira1,2. 1. Discipline of Pediatrics, School of Women's and Children's Health, Faculty of Medicine University of New South Wales Sydney New South Wales Australia. 2. Respiratory Department Sydney Children's Hospital Randwick Sydney New South Wales Australia.
Abstract
BACKGROUND: Oseltamivir is recommended in the treatment of influenza illness in high-risk populations, including those with chronic heart and lung diseases. OBJECTIVES: We conducted a systematic review and meta-analysis to determine the rate of use and effectiveness of oseltamivir in these groups of patients. METHODS: The protocol for the systematic review was registered on PROSPERO (CRD42019125998). Medline, EMBASE, Cochrane CENTRAL, and CINAHL were searched for observational studies and randomized controlled trials published up to 16 February 2020. Quality appraisal of final studies was conducted using GRADE guidelines. Data were extracted using a predeveloped template. Main outcomes measured included the rate of use of oseltamivir for influenza-like-illness and its effectiveness in reducing disease severity in patients with cardiopulmonary diseases. Outcomes measured for effectiveness were influenza-related complications (respiratory infections and asthma exacerbations), hospitalization rates, and time to freedom from illness. Risk of bias was assessed using Cochrane's Risk of Bias 2.0 tool for randomized trials and Cochrane's Risk of Bias in nonrandomized Studies of Interventions tool for nonrandomized trials. Where data were available, pooled analyses were conducted. Dichotomous variables were evaluated using the Mantel-Hansel method. A random effect model was applied. Summary measures were reported as risk ratios where relevant. RESULTS: Our systematic review identified nine studies. Oseltamivir use ranged from 25% to 100%. When oseltamivir group was compared to placebo, rates of respiratory tract infections reduced by 28% (RR = 0.72, 95% CI = 0.59-0.90), hospitalization reduced by 52% (RR = 0.48, 95% CI = 0.28-0.80) and median time to illness alleviation decreased by 10.4 to 120 hours. There was no significant reduction in asthma exacerbation rates. CONCLUSIONS: Our systematic review suggests that the use of oseltamivir is beneficial in reducing disease severity, however, its use in high-risk population remains suboptimal.
BACKGROUND: Oseltamivir is recommended in the treatment of influenza illness in high-risk populations, including those with chronic heart and lung diseases. OBJECTIVES: We conducted a systematic review and meta-analysis to determine the rate of use and effectiveness of oseltamivir in these groups of patients. METHODS: The protocol for the systematic review was registered on PROSPERO (CRD42019125998). Medline, EMBASE, Cochrane CENTRAL, and CINAHL were searched for observational studies and randomized controlled trials published up to 16 February 2020. Quality appraisal of final studies was conducted using GRADE guidelines. Data were extracted using a predeveloped template. Main outcomes measured included the rate of use of oseltamivir for influenza-like-illness and its effectiveness in reducing disease severity in patients with cardiopulmonary diseases. Outcomes measured for effectiveness were influenza-related complications (respiratory infections and asthma exacerbations), hospitalization rates, and time to freedom from illness. Risk of bias was assessed using Cochrane's Risk of Bias 2.0 tool for randomized trials and Cochrane's Risk of Bias in nonrandomized Studies of Interventions tool for nonrandomized trials. Where data were available, pooled analyses were conducted. Dichotomous variables were evaluated using the Mantel-Hansel method. A random effect model was applied. Summary measures were reported as risk ratios where relevant. RESULTS: Our systematic review identified nine studies. Oseltamivir use ranged from 25% to 100%. When oseltamivir group was compared to placebo, rates of respiratory tract infections reduced by 28% (RR = 0.72, 95% CI = 0.59-0.90), hospitalization reduced by 52% (RR = 0.48, 95% CI = 0.28-0.80) and median time to illness alleviation decreased by 10.4 to 120 hours. There was no significant reduction in asthma exacerbation rates. CONCLUSIONS: Our systematic review suggests that the use of oseltamivir is beneficial in reducing disease severity, however, its use in high-risk population remains suboptimal.
Authors: Susan E Coffin; Kateri Leckerman; Ron Keren; Matthew Hall; Russell Localio; Theoklis E Zaoutis Journal: Pediatr Infect Dis J Date: 2011-11 Impact factor: 2.129
Authors: Fiona Havers; Swathi Thaker; Jessie R Clippard; Michael Jackson; Huong Q McLean; Manjusha Gaglani; Arnold S Monto; Richard K Zimmerman; Lisa Jackson; Josh G Petrie; Mary Patricia Nowalk; Krissy K Moehling; Brendan Flannery; Mark G Thompson; Alicia M Fry Journal: Clin Infect Dis Date: 2014-07-16 Impact factor: 9.079
Authors: F Y Aoki; M D Macleod; P Paggiaro; O Carewicz; A El Sawy; C Wat; M Griffiths; E Waalberg; P Ward Journal: J Antimicrob Chemother Date: 2003-01 Impact factor: 5.790
Authors: Mercedes Bueno; Cristina Calvo; Ana Méndez-Echevarría; María Isabel de José; Mar Santos; Jaime Carrasco; Miriann Tovizi; Sara Guillén; Ana de Blas; Marta Llorente; Alfredo Tarrago; Luis Escosa; María José Cilleruelo; Cristina Tomatis; Daniel Blazquez; Enrique Otheo; Diana Mazagatos; Maria Luz García-García Journal: Pediatr Infect Dis J Date: 2013-10 Impact factor: 2.129
Authors: Christopher C Butler; Alike W van der Velden; Emily Bongard; Benjamin R Saville; Jane Holmes; Samuel Coenen; Johanna Cook; Nick A Francis; Roger J Lewis; Maciek Godycki-Cwirko; Carl Llor; Sławomir Chlabicz; Christos Lionis; Bohumil Seifert; Pär-Daniel Sundvall; Annelies Colliers; Rune Aabenhus; Lars Bjerrum; Nicolay Jonassen Harbin; Morten Lindbæk; Dominik Glinz; Heiner C Bucher; Bernadett Kovács; Ruta Radzeviciene Jurgute; Pia Touboul Lundgren; Paul Little; Andrew W Murphy; An De Sutter; Peter Openshaw; Menno D de Jong; Jason T Connor; Veerle Matheeussen; Margareta Ieven; Herman Goossens; Theo J Verheij Journal: Lancet Date: 2019-12-12 Impact factor: 79.321
Authors: Ranjani Somayaji; Christopher H Goss; Umer Khan; Moni Neradilek; Kathleen M Neuzil; Justin R Ortiz Journal: Clin Infect Dis Date: 2017-06-15 Impact factor: 9.079
Authors: Tom Jefferson; Mark A Jones; Peter Doshi; Chris B Del Mar; Rokuro Hama; Matthew J Thompson; Elizabeth A Spencer; Igho Onakpoya; Kamal R Mahtani; David Nunan; Jeremy Howick; Carl J Heneghan Journal: Cochrane Database Syst Rev Date: 2014-04-10